🇺🇸 Adalimumab (40 mg) in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 11

Most-reported reactions

1. Headache — 2 reports (18.18%)
2. Abdominal Wall Abscess — 1 report (9.09%)
3. Abscess Drainage — 1 report (9.09%)
4. Adrenal Insufficiency — 1 report (9.09%)
5. Aortitis — 1 report (9.09%)
6. B-Cell Lymphoma — 1 report (9.09%)
7. Blood Pressure Systolic Increased — 1 report (9.09%)
8. Bronchitis — 1 report (9.09%)
9. Csf Protein Increased — 1 report (9.09%)
10. Diffuse Alveolar Damage — 1 report (9.09%)

Source database →

Frequently asked questions

Is Adalimumab (40 mg) approved in United States?

Adalimumab (40 mg) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Adalimumab (40 mg) in United States?

Janssen Scientific Affairs, LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.